154 related articles for article (PubMed ID: 11362623)
1. New antiretroviral strategies: interview with Marcus Conant, M.D. Interview by John S. James.
Conant M
AIDS Treat News; 1995 Aug; (no 228):1-3. PubMed ID: 11362623
[TBL] [Abstract][Full Text] [Related]
2. Combination treatment and single drugs: interview with Margaret Poscher, M.D. Interview by John S. James.
Poscher M
AIDS Treat News; 1995 Jul; (no 226):2-4 contd. PubMed ID: 11362613
[TBL] [Abstract][Full Text] [Related]
3. Potent new AIDS drugs underscore promise of combination therapy.
AIDS Alert; 1996 Jan; 11(1):1-4. PubMed ID: 11363225
[TBL] [Abstract][Full Text] [Related]
4. Combination treatment and single drugs: interview with Margaret Poscher, M.D. Interview by John S. James.
Poscher M
AIDS Treat News; 1995 Jul; (no 227):2-4 concl. PubMed ID: 11362619
[TBL] [Abstract][Full Text] [Related]
5. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
[TBL] [Abstract][Full Text] [Related]
6. FDA triple header. Food and Drug Administration.
Smart T
GMHC Treat Issues; 1995 Nov; 9(11):1-3. PubMed ID: 11362986
[TBL] [Abstract][Full Text] [Related]
7. New drugs for HIV infection.
Med Lett Drugs Ther; 1996 Apr; 38(972):35-7. PubMed ID: 8606677
[TBL] [Abstract][Full Text] [Related]
8. Nipping HIV in the bud.
Smart T
GMHC Treat Issues; 1996 Aug; 10(8):3-6. PubMed ID: 11363719
[TBL] [Abstract][Full Text] [Related]
9. 3TC and saquinavir: we need them now.
Baker R
BETA; 1995 Sep; ():3. PubMed ID: 11362889
[TBL] [Abstract][Full Text] [Related]
10. Conference looks at HIV drug resistance.
Chang HE
GMHC Treat Issues; 1995 Sep; 9(9):6-8. PubMed ID: 11362910
[TBL] [Abstract][Full Text] [Related]
11. FDA antiviral advisory hearings on lamivudine (Epivir, 3TC), saquinavir (Invirase), stavudine (Zerit, d4T), November 6-8. Food and Drug Administration.
AIDS Treat News; 1995 Oct; (no 233):4-5. PubMed ID: 11363038
[TBL] [Abstract][Full Text] [Related]
12. Protease inhibitor trials moving to next phase.
AIDS Alert; 1995 Aug; 10(8):100-1. PubMed ID: 11362675
[TBL] [Abstract][Full Text] [Related]
13. Top AIDS researchers' strategy for antiretroviral treatment.
AIDS Alert; 1996 Sep; 11(9):97-100. PubMed ID: 11363728
[TBL] [Abstract][Full Text] [Related]
14. Combination antiretroviral treatment: new views, evolving practices.
James JS
AIDS Treat News; 1995 Jul; (no 226):1-2. PubMed ID: 11362612
[TBL] [Abstract][Full Text] [Related]
15. 3TC/AZT: just another combination.
GMHC Treat Issues; 1995 Dec; 9(12):2. PubMed ID: 11362997
[TBL] [Abstract][Full Text] [Related]
16. Lamivudine (3TC) approved for combination use with AZT.
James JS
AIDS Treat News; 1995 Dec; (no 236):1-5. PubMed ID: 11363049
[TBL] [Abstract][Full Text] [Related]
17. A closer look at 3TC. Interview by Mark Mascolini.
Rubin M
J Int Assoc Physicians AIDS Care; 1995 Jul; 1(6):21-5. PubMed ID: 11362724
[TBL] [Abstract][Full Text] [Related]
18. Protease inhibitors and prevention of cross resistance.
Levin J
AIDS Treat News; 1995 Oct; (no 232):1-3. PubMed ID: 11362875
[TBL] [Abstract][Full Text] [Related]
19. Update on HIV protease inhibitors.
Vella S
AIDS Clin Care; 1995 Oct; 7(10):79-82, 88. PubMed ID: 11362832
[TBL] [Abstract][Full Text] [Related]
20. How far can you knock down HIV? An interview with David D. Ho, MD. Interview by Mark Mascolini.
Ho DD
J Int Assoc Physicians AIDS Care; 1997 Jun; 3(6):40-4. PubMed ID: 11364429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
